Targeted treatment options currently under investigation such as NOV03 and CyclASol®, based on a water- and preser-vative-free technology, offer hope that new drugs can provide more patients with a satisfying treatment solution—to improve ocular surface damage and DED symptoms, as well as preserve vision and quality of life.